OXAPROZIN

Post-LOE

oxaprozin

Teva

ANDAORALTABLET

Approved

Aug 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

OXAPROZIN (oxaprozin) by Teva is cyclooxygenase inhibitors [moa]. Approved for rheumatoid arthritis, rheumatoid arthritis, for relief of the signs and symptoms of osteoarthritis. First approved in 2001.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Cyclooxygenase Inhibitors

Indications (2)

rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis

Clinical Trials (1)

NCT03350386Phase 1Completed

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Started Nov 2017

12 enrolled

Healthy

Worked on OXAPROZIN at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.